KLI

Expression of the immune checkpoint molecule V-set immunoglobulin domain-containing 4 is associated with poor prognosis in patients with advanced gastric cancer

Metadata Downloads
Abstract
Abstract
Background: Recent clinical studies on immune checkpoint (IC) inhibitors in the context of advanced gastric cancer (AGC) have failed to show significant survival benefits but have suggested the possible role of IC inhibitors in anti-AGC immunity. Considering the low efficacy of targeted drugs in AGC, there is an urgent need for the discovery of new targets for the development of immunotherapeutics and prognostic markers for patient selection. This study aimed to investigate the expression of a new IC molecule, V-set Ig domain-containing 4 (VSIG4), and its clinical significance in AGC and other major cancers.

Methods: We analyzed the expression of VSIG4 and its correlation with survival in various carcinomas, including 882 surgically resected samples from patients with stage II-III AGC (two academic hospitals).

Results: VSIG4 positivity in AGC was significantly associated with overall survival (OS; Hazard ratio (HR) = 2.661, 95% confidence interval [CI] = 2.012-3.519, P < 0.001) and event-free survival (HR = 2.8, 95% CI = 2.18-3.72, P < 0.001). These findings were successfully validated in independent cohorts. VSIG4 expression was also significantly correlated with low intratumoral CD8 + T-cell infiltration (CD8i) (P = 0.029) and high Foxp3 + /CD8i ratio (P = 0.026), which is consistent with the previously reported immunological function of VSIG4. However, VSIG4 expression was not associated with survival in other cancers (colon, P = 0.459; lung, P = 0.275; kidney, P = 0.121; breast, P = 0.147).

Conclusion: Our results suggest that VSIG4 is an independent prognostic factor in AGC and also implies that VSIG4 is a second-tier IC molecule in AGC, thus, providing an important basis for the development of gastric cancer-specific immunotherapeutics.

Keywords: Advanced gastric cancer; Immune checkpoint molecule; Immunotherapy; Tumor microenvironment; V-set Ig domain-containing 4.
Author(s)
김소운노진박영수박찬식유민희이혜승
Issued Date
2021
Type
Article
Keyword
Advanced gastric cancerImmune checkpoint moleculeImmunotherapyTumor microenvironmentV-set Ig domain-containing 4.
DOI
10.1007/s10120-020-01120-1
URI
https://oak.ulsan.ac.kr/handle/2021.oak/8440
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_proquest_miscellaneous_2442596727&amp;context=PC&amp;vid=ULSAN&amp;lang=ko_KR&amp;search_scope=default_scope&amp;adaptor=primo_central_multiple_fe&amp;tab=default_tab&amp;query=any,contains,Expression%20of%20the%20immune%20checkpoint%20molecule%20V-set%20immunoglobulin%20domain-containing%204%20is%20associated%20with%20poor%20prognosis%20in%20patients%20with%20advanced%20gastric%20cancer&amp;offset=0&amp;pcAvailability=true
Publisher
Gastric Cancer
Location
미국
Language
영어
ISSN
1436-3291
Citation Volume
24
Citation Number
2
Citation Start Page
327
Citation End Page
340
Appears in Collections:
Medicine > Medicine
공개 및 라이선스
  • 공개 구분공개
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.